RxDoctor Payments Data

Martha Baumann

Nurse Practitioner · Centerville, OHNPI 1083171300

Payments from drug & device makers

$3,828in general payments, 2019–2025

Across 297 payments — averaging $12.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$794
  • Biohaven Pharmaceuticals, Inc.$461
  • Teva Pharmaceuticals USA, Inc.$347
  • Biogen$334
  • Lilly USA, LLC$277
  • Sunovion Pharmaceuticals Inc.$217
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,821100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,828 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$60,547
Medicare patients
272
Services billed
547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate22$103,328
IngrezzaValbenazine Tosylate12$93,608
UbrelvyUbrogepant28$31,330
BriviactBrivaracetam12$18,050
Aimovig AutoinjectorErenumab-Aooe17$13,160
Aripiprazole14$11,186
Rivastigmine37$9,732
Carbidopa-Levodopa ErCarbidopa/Levodopa91$8,450
Entacapone34$8,153
Levetiracetam207$6,911
Gabapentin291$6,893
Pregabalin90$4,920
Memantine Hcl ErMemantine Hcl23$4,885
Lacosamide35$4,617
Carbidopa-LevodopaCarbidopa/Levodopa204$4,486

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$28$103,32822 claims
Neurocrine Biosciences, Inc.Ingrezza$69$93,60812 claims
AbbVieUbrelvy$794$31,33028 claims
UCB, Inc.Briviact$90$18,05012 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$92$85719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Centerville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →